OMED - OncoMed Pharmaceuticals, Inc.
| Previous Close | 1.91 |
| Open | 1.93 |
| Bid | 2.07 x 1100 |
| Ask | 2.13 x 1800 |
| Day's Range | 1.90 - 2.15 |
| 52 Week Range | 1.74 - 5.56 |
| Volume | 52,456 |
| Avg. Volume | 74,355 |
| Market Cap | 81.608M |
| Beta (3Y Monthly) | 1.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.17 |
- GlobeNewswire•7 days ago
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting
REDWOOD CITY, Calif., Oct. 09, 2018 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel.
- GlobeNewswire•22 days ago
OncoMed to Present at the Cantor Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 24, 2018-- OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that ...
- GlobeNewswire•22 days ago
OncoMed Announces Publication of Phase 1a Data of Navicixizumab
REDWOOD CITY, Calif., Sept. 24, 2018-- OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that ...
- GlobeNewswire•26 days ago
OncoMed Provides Update on Navicixizumab Partnership
REDWOOD CITY, Calif., Sept. 20, 2018-- OncoMed Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that ...
- Simply Wall St.•last month
Can OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improve Your Portfolio Returns?
Anyone researching OncoMed Pharmaceuticals Inc (NASDAQ:OMED) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...
- GlobeNewswire•2 months ago
OncoMed to Present at Two Upcoming Investor Conferences in September
REDWOOD CITY, Calif., Aug. 29, 2018-- OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that ...
- Zacks•2 months ago
OncoMed Pharmaceuticals (OMED) Reports Q2 Loss, Misses Revenue Estimates
OncoMed (OMED) delivered earnings and revenue surprises of 56.52% and -8.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
OncoMed: 2Q Earnings Snapshot
On a per-share basis, the Redwood City, California-based company said it had a loss of 10 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- GlobeNewswire•2 months ago
OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights
-Company prioritizes its navicixizumab resources in platinum-resistant ovarian cancer; prepares to share data in Q4 of 2018-. -Cash runway extended by an additional quarter to YE 2019-. REDWOOD CITY, Calif., ...
- Associated Press•5 months ago
OncoMed: 1Q Earnings Snapshot
The Redwood City, California-based company said it had a loss of 15 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- Zacks•5 months ago
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.
- Zacks•6 months ago
Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y
Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.
- InvestorPlace•6 months ago
3 Biotech Stocks That Will Thrive Amid Market Instability
The U.S. stock market is facing a severe volatility since the last couple of months despite a strong start this year. This downside can mainly be attributable to a potentially damaging trade war between the world’s two largest economies, United States and China, since this February.Source: Shutterstock
- Zacks•7 months ago
Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?
Investors certainly have to be happy with OncoMed Pharmaceuticals, Inc. (OMED) and its short term performance
- Simply Wall St.•7 months ago
OncoMed Pharmaceuticals Inc (NASDAQ:OMED): What Are The Future Prospects?
Looking at OncoMed Pharmaceuticals Inc’s (NASDAQ:OMED) earnings update in December 2017, analyst consensus outlook appear cautiously optimistic, as a 20.56% increase in profits is expected in the upcoming year, againstRead More...
- Insider Monkey•7 months ago
Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial dividends, to small, emerging companies without any products on the market or revenue, but backed by their research into novelty therapies for various illnesses. When looking for healthcare stocks […]
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of OMED earnings conference call or presentation 8-Mar-18 9:30pm GMT
Q4 2017 OncoMed Pharmaceuticals Inc Earnings Call
- Simply Wall St.•7 months ago
When Can We Expect A Profit From OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?
OncoMed Pharmaceuticals Inc’s (NASDAQ:OMED): OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The US$109.03M market-cap posted a loss in its most recent financial year ofRead More...
- Associated Press•7 months ago
OncoMed tops Street 4Q forecasts
The Redwood City, California-based company said it had profit of 25 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
